Galapagos NV has announced that its service division, BioFocus DPI, has entered into an agreement to supply small molecule compounds for drug discovery to the Johnson & Johnson Pharmaceutical Research & Development Division of Janssen Pharmaceutica NV.

Under the terms of the two-year agreement, BioFocus DPI will provide access to compounds from its SoftFocus small molecule libraries and will also generate customer specific compound library sets for use in J&JPRD's drug discovery programs. Financial terms were not disclosed.
 
"This supply agreement is a natural expansion of our drug discovery relationship with J&JPRD.  It will give J&JPRD access to highly targeted drug building blocks for their drug discovery programs," said Onno van de Stolpe, Chief Executive Officer of Galapagos.